Please find enclosed herewith intimation with respect to Appointment of Secretarial Auditor of the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Accretion Nutraveda reported strong FY2026 results with revenue of Rs 33.60 crore (up 110% from Rs 16 crore), profit after tax of Rs 5.07 crore (up 103%), and EPS of Rs 9.35. The company listed on BSE SME in February 2026 via IPO raising Rs 24.77 crore, with Rs 18.21 crore deployed as of March 2026. Two independent directors - Mr. Arun Dash and Mr. Mahipal Singh Chouhan - resigned on the same day citing personal/preprofessional commitments, while two new independent directors - Mr. Chand Rameshbhai Kanabar and Ms. Grishma A Shewale - were appointed as Additional Directors, subject to shareholder approval. Secretarial auditors were reappointed and new internal auditors appointed for FY2026-27.
The simultaneous resignation of two independent directors on the same day as listing anniversary raises governance concerns, though replacements have been appointed. Strong financial performance with 100%+ growth provides fundamental support for the stock.